Glycyrrhizic Acid Alleviates Osimertinib-Induced Cutaneous Toxicity by Inhibiting Keratinocyte Apoptosis and Inflammation

This study investigates the potential of glycyrrhizic acid (GA), a key component of licorice, to alleviate cutaneous toxicity caused by Osimertinib, a treatment for EGFR-mutated non-small cell lung cancer. Mice treated with Osimertinib exhibited symptoms such as rash, itching, and hair loss, along with increased keratinocyte apoptosis and inflammation. GA, administered at 30 mg/kg/day, was found to reduce the severity of these symptoms, restore epidermal thickness, decrease DNA damage, and lower inflammatory factor expression. The findings suggest that GA could serve as a promising adjunct therapy to mitigate Osimertinib-induced cutaneous toxicity, potentially improving the quality of life for affected patients.